The risk of innovation: measuring drug clinical development in Brazil Online publication date: Tue, 31-Jul-2018
by Michele De Medeiros Rocha; Danilo Garbazza Vieira; Gilson Brito Alves Lima; Emmanuel Paiva De Andrade; Osvaldo Luis Gonçalves Quelhas
International Journal of Business Innovation and Research (IJBIR), Vol. 17, No. 1, 2018
Abstract: Although risk is inherent in innovation, the pharmaceutical sector still leads research and development (R&D) investments. Therefore, the awareness of potential risks is especially important for this sector that spends approximately 70% of the total cost of new drug development on clinical trials. The economic crisis in Europe and its reimbursement system has made emerging countries, like Brazil, potential strategic markets for the return of these high investments. Using a public database (ClinicalTrials.gov), this study estimated the probabilities of failure and success of clinical trials in Brazil up to approval by the regulatory authority. The results showed the risk in conducting phase 3 clinical trials, the most extensive and complex phase, is considered high (26.7%). On the other hand, regulatory approval represents a high success rate, since over 90% of the drugs with positive results in phase 3 were approved by the Brazilian Agency.
Online publication date: Tue, 31-Jul-2018
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Business Innovation and Research (IJBIR):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email email@example.com